The global cell-based assays market size was valued at USD 16.85 billion in 2023 and is anticipated to reach around USD 38.48 billion by 2033, growing at a CAGR of 8.64% from 2024 to 2033.
Access our Healthcare Data Intelligence Tool with 10000+ Database, Visit: Towards Healthcare
The U.S. cell-based assays market size reached USD 11.82 billion in 2023 and is anticipated to be worth around USD 27.52 billion by 2033, poised to grow at a CAGR of 8.85% from 2024 to 2033.
North America accounted for the larger market share during the forecast period. The increasing prevalence of chronic diseases such as cancer, cardiovascular, cancer, diabetes, neurological disorders, osteoarthritis, diabetes and others, sophisticated healthcare infrastructure, presence of prominent market players, increasing R&D investment, and high adoption of cell-based assays is expected to drive the demand for cell-based assays for newer drug discoveries, making it a crucial factor for the growth of the market in the region. In addition, several market players are focusing on partnerships or strategic collaborations for the development of cell-based assays in the region.
For instance, in March 2022, headquartered in the United States, a pioneer and rapidly growing company in offering advanced solutions and technical support to life science sector, Promega Corporation announced a strategic business activity with FUJIFILM Cellular Dynamics Inc in order to advance novel assay systems for novel drug discovery. Under the collaboration, the companies aim to develop novel assays to detect and monitor cellular biology that reflects cells behavior in the human body.
On the other hand, the Asia Pacific is expected to witness the fastest growth during the forecast period. The Asia Pacific region has witnessed a surge in research and development activities in the field of life sciences and biotechnology. Governments, academic institutions, and private organizations are investing in research infrastructure and promoting collaborations. This has led to the expansion of cell-based assay research, driving the market's growth.
The Asia Pacific region is experiencing an increasing prevalence of chronic diseases such as cancer, cardiovascular diseases, and diabetes. Cell-based assays play a crucial role in understanding disease mechanisms, identifying potential therapeutic targets, and testing drug efficacy. The need for effective diagnostics and personalized medicine approaches drives the adoption of cell-based assays in the region.
Europe is expected to remain another lucrative marketplace for cell-based assay market players. Europe’s cell-based assay market is driven by factors such as increasing research activities, a well-established pharmaceutical industry, the prevalence of chronic diseases, technological advancements, supportive government initiatives, presence of major market players and the adoption of personalized medicine approaches. As these trends continue, the market is expected to expand further in the region.
The Europe cell-based assays market size surpassed USD 4.96 billion in 2023 and is projected to reach USD 11.93 billion by 2033.
| Year | Market Share (USD Billion) |
| 2023 | 4.96 |
| 2024 | 5.40 |
| 2025 | 5.88 |
| 2026 | 6.42 |
| 2027 | 7.00 |
| 2028 | 7.65 |
| 2029 | 8.37 |
| 2030 | 9.16 |
| 2031 | 10.04 |
| 2032 | 11.01 |
| 2033 | 11.93 |
The cell-based assays market plays around the production and services related to cell-based assays. The global cell-based assays market carries a wide range of reagents, consumables, instruments, and services used in conducting cell-based assays for research, drug discovery, and toxicity testing applications. The market includes both the products and services provided by manufacturers, as well as the contract research organizations (CROs) and academic research institutions that utilize cell-based assays for their research.
The cell-based assay is a technique widely used to study the characteristics and responses of cells in a controlled laboratory setting. These assays involve the use of live cells, either in culture or derived from organisms, to investigate various cellular processes, such as cell viability, proliferation, apoptosis, gene expression, protein production, signaling pathways, and drug responses. Cell-based assays provide valuable insights into cellular biology, disease mechanisms, drug discovery, and toxicity testing.
Cell-based assays are crucial in evaluating the toxicity of chemicals, drugs, or environmental agents. Assays like cell viability assays, apoptosis assays, or cell cycle analysis can help assess the adverse effects of compounds on cellular health and function.
The global cell-based assays market is expected to witness significant growth during the forecast period owing to the rising focus on drug development globally. Cell-based assays play a critical role in early-stage drug discovery by enabling the evaluation of compound efficacy, toxicity, and safety profiles. The continuous need for new drugs and the expanding pharmaceutical and biotechnology industries fuel the demand for cell-based assays.
Growing emphasis on personalized medicine, rising government investments in research and developments, and expansion of pharmaceutical and biotechnology industries are a few growth factors that collectively contribute to expanding the cell-based assay market. The market is highly competitive, with critical players offering a wide range of products and services, including reagents, assay kits, instruments, and contract research services. Continued innovation, product development, strategic collaborations, and the increasing adoption of cell-based assays across various research fields are expected to drive the growth of the market in the coming years.
| Report Coverage | Details |
| Market Size in 2023 | USD 16.85 Billion |
| Market Size by 2033 | USD 38.48 Billion |
| Growth Rate from 2024 to 2033 | CAGR of 8.64% |
| Largest Market | North America |
| Base Year | 2023 |
| Forecast Period | 2024 To 2033 |
| Segments Covered | By Type, By Products & Services, By Application, By Technology, and By End-use |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Driver:
Increasing prevalence of the chronic disorder
The rising prevalence of chronic disorders acts as a significant driver for the cell-based assays market due to the need for understanding, treatment, and management of these disorders. Chronic disorders such as cardiovascular diseases, diabetes, cancer and neurodegenerative diseases require a deeper understanding of their underlying mechanisms. Cell-based assays provide a precise tool for studying disease pathology, identifying key cellular targets, and investigating disease progression. Cell-based assays allow researchers to mimic disease conditions in vitro and assess cellular responses to various stimuli or treatments. The rising prevalence of chronic disorders fuels the demand for cell-based assays as researchers seek to gain insights into disease mechanisms.
Cell-based assays even play a crucial role in drug discovery and development processes, enabling the screening of compounds, identification of potential drug candidates, and evaluation of their efficacy and safety profiles. With the increasing prevalence of chronic disorders, the demand for cell-based assays in drug discovery rises, as researchers strive to find novel therapeutic options.
Restraints:
Restrictions on reagent use
The restrictions on reagent use are projected to hamper the growth of the global cell-based assay market. In addition, the high instrument costs are likely to limit the expansion of the global cell-based assay market during the forecast period. Some cell-based assays require specific reagents, such as antibodies, growth factors, cytokines, or fluorescent dyes, to detect and measure cellular responses. These specialized reagents may be subject to restrictions due to intellectual property rights, licensing agreements, or limited commercial availability. If researchers or assay developers face challenges in accessing these critical reagents, it can impede the progress and adoption of certain cell-based assays.
Opportunities:
Deployment of 3D cell culture practices
3D cell culture models provide a more relevant environment. The opportunities for the market are available in leveraging 3D cell culture models to enhance the predictive power and reliability of cell-based assays. 3D cell culture models offer the potential to create disease-specific microenvironments, allowing researchers to study disease mechanisms and develop better models for drug discovery and development. These models can be tailored to replicate specific disease conditions, such as cancer, neurodegenerative disorders, or organ-specific diseases. By integrating 3D cell culture with cell-based assays, researchers can gain insights into disease pathogenesis, identify therapeutic targets, and evaluate personalized treatment strategies.
The assay kits products & services segment is expected to expand at a robust growth rate during the forecast period owing to its utility in numerous biopharmaceutical applications. These kits are used to study various aspects of cellular behavior such as cell cycle progression, migration, and invasion, as well as to determine the content of key cell components that are frequently used to monitor the health of cells in culture and their response to different stimuli.
Based on the technology, the global cell-based assay market is segmented into automated handling, flow cytometry, label-free detection, high-throughput screening, and others.
The high-throughput screening segment of the technology is predicted to grow at the most significant rate. High throughput screening technology is widely used in drug discovery processes that boost the speed of cellular and biochemical events. High-throughput screening technology offers cost-effective screening approaches. By screening large compound libraries in a single experiment, researchers can optimize resource utilization, including reagents, consumables, and laboratory equipment. High-throughput screening reduces the need for individual compound testing, minimizing costs associated with labor, time, and materials.
The drug discovery segment is expected to dominate the market over the forecast period owing to the increasing investment by biopharmaceutical companies in R&D activities, the increasing number of CROs providing drug discovery services, the introduction of new drugs, rising incidence of chronic diseases, such as cancer, cardiovascular disorders, diabetes, and others is boosting the demand for cell-based assays for the development newer drug discoveries.
Cell-based assays evaluate a drug's effectiveness in a cellular environment, which is important for comprehending how a drug behaves in a biological system and for aligning readouts with a biomarker that can be translated. Several phases of drug development employ cell-based assays. Prior to testing a medication candidate on live animals or in later stages of clinical trials, specific cell-based in vitro experiments must be completed. The biological activity of the test substances naturally becomes the main focus of drug discovery.
Throughout the drug development process, a cell-based assay can also be used to evaluate the "potency" of drug products. For the initial "hit discovery" to find a medicine with verified activity against a biological target, cell-based tests can be performed. Information on complex biology, extensive screening libraries, and cutting-edge drug screening platforms are all necessary for this stage of drug discovery.
The biotechnology and pharmaceutical companies segment held the largest share of the market in 2023; the segment is expected to sustain its dominance during the forecast period. Cell-based assays are commonly used by multiple pharmaceutical companies as well as biotechnology companies. In recent years, the biotechnology and pharmaceutical sectors have witnessed immense growth, a significant factor in the segment’s growth.
The contract research organizations (CROs) segment is expected to be the most attractive segment during the forecast period. CROs use cell-based assays for high-throughput screening of small molecule libraries or compound collections. By employing automated systems and robotic platforms, they can test thousands of compounds against specific cellular targets or disease models. Cell-based assays enable efficient and rapid screening, identifying potential drug candidates for further development.
Cell-based assays enable CROs to provide efficient, cost-effective, and high-quality services to their clients, facilitating the advancement of pharmaceutical and biotechnological research.
Segments Covered in the Report:
By Type
By Products & Services
By Application
By Technology
By End-use
By Geography
PROCEED TO BUY :
ASK FOR SAMPLE
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
